Placebo for pegozafermin. combined integral administration device: pre-filled syringe - please refer to the impd pegozafermin section 3.2.p.7 container closure system for detailed description.
Sponsors
89bio Inc.
Conditions
Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Compensated CirrhosisMetabolic Dysfunction-Associated Steatotic Liver Disease(MASH) / Nonalcoholic Steatohepatitis (NASH) With FibrosisSevere Hypertriglyceridemia
Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Severe Hypertriglyceridemia (SHTG)
Active, not recruitingCTIS2023-503576-25-00
Start: 2023-09-22Target: 169Updated: 2025-07-29
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
RecruitingCTIS2023-509912-27-00
Start: 2024-11-07Target: 260Updated: 2026-01-26
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Compensated Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)
RecruitingCTIS2023-510395-31-00
Start: 2024-10-30Target: 155Updated: 2026-01-27